Thermo Fisher and Juno sign seven-year CAR-T tech deal

By Flora Southey contact

- Last updated on GMT


Related tags: Thermo fisher, Thermo fisher scientific, Thermo electron

Juno Therapeutics will use Thermo Fisher Scientific’s Cell Therapy Systems (CTS) technology to develop CAR T therapies for cancer treatments.

The agreement will see Thermo Fisher supply Juno with CTS Dynabeads CD3/CD28 for seven years in a nonexclusive licensing deal.

Thermo Fisher said the magnetic beads – which it makes at its manufacturing facility in Vilnius, Lithuania – activate and expand T cells specially designed to identify and combat cancer cells in patients. 

“Thermo Fisher’s Dynabeads T cell expansion bead platform is already proven in commercial manufacturing, and is known for greater stability and scalability, which are critical requirements for CAR T manufacturers,” ​Thermo Fisher COO Mark Stevenson told us.

According to Stevenson, the firms have worked together since Juno was founded in 2013.

“Today’s announcement formalises the relationship to allow maximum collaboration to bring product to patients,” ​he said.

Financial details of the deal were not disclosed.

Thermo Fisher also supplies​ its CTS Dynabeads technology for CAR-T immunotherapies to Swiss firm Novartis.

The US Food and Drug Administration (FDA) approved​ Novartis’ CAR-T immunotherapy Kymriah (tisagenlecleucel) in August last year, making it the first commercially available CAR-T treatment in the US.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more